A Phase 1 interventional study of MK-7762 (TBD09) and Placebo in Tuberculosis, sponsored by Gates Medical Research Institute. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-04.
Sponsored by Gates Medical Research Institute · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 129 studies in Tuberculosis with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Tuberculosis · United States.
Among the 129 studies in Tuberculosis with a site in United States, this one is the 32nd largest by enrollment of the 94 interventional ones that give a count, is one of 3 that started in 2023, is one of 44 in phase 1, and was the 125th registered.
1,173 studies on the registry are indexed under Tuberculosis; 177 are open to participants now.
Browse Tuberculosis studies →4 of the 129 studies in Tuberculosis with a site in United States are open now. Recruiting first, the newest first:
University of Pennsylvania · Sites in United States
Ages 21+
Columbia University · Sites in United States
Ages 18+ · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States, Mexico
Ages 18–99
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 2–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 112 Tuberculosis studies recruiting now, 65 (58%) set no upper age limit and 37 (33%) stop at 75 or younger; 49 take children under 18; 31 take healthy volunteers.
This study: 19 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
129 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 13 · Phase 3 8 · Phase 4 8
First in 1992; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 119 is below the median of 150 across 822 interventional studies indexed under Tuberculosis.
Median enrollment 56 across the 94 interventional studies, 151 across the 32 observational. Of the 117 that completed or were terminated, 35 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 129 have an industry lead sponsor. The 10 most frequent:
Gates Medical Research Institute is the lead sponsor of 12 studies on the registry; 2 are open to participants now.
Gates Medical Research Institute has 3 studies filed under Tuberculosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Tuberculosis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07737275Columbia UniversityScreening With Portable X-rays for Rapid Recognition of TB | 2027-05-25 |
Add it to your calendar (.ics) → With an account.
Among the 129 studies in Tuberculosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of single and then multiple doses of MK-7762 (TBD09) in healthy volunteers in the context of a first-in-human study. The effect of food on the rate and extent of absorption of a single oral dose of MK-7762 (TBD09) will also be evaluated.
This is a 2-part blinded, placebo-controlled, combined single ascending dose with a food effect cohort and multiple ascending dose trial to be conducted in one trial center in the United States.
Part 1 has a single ascending dose (SAD) design with up to 5 planned dose levels. Based on the interim PK results reviewed for the dose escalation decisions, a dose will be selected for administration to a sixth cohort both in fed and fasted states to evaluate the effect of food on MK-7762 (TBD09).
Safety will be assessed throughout the study; cardiac monitoring/serial ECGs and serial blood samples will be collected for the safety and PK assessment of MK7762 (TBD09). Dose escalation to the next cohort (i.e., dose level) will not take place until the Sponsor, in conjunction with the Principal Investigator, has determined that adequate safety, tolerability (and PK for the later cohorts) from the previous cohort has been demonstrated to permit proceeding to the next cohort.
Interim PK analyses will be performed for the dose escalation decisions (after cohorts 1 and 2 are completed), to select the intermediate dose for the food effect cohort, and to reconsider the sampling time points as the trial progresses. All samples will be sent for analysis and the bioanalytical lab will be unblinded and only run the analysis on active treatment participants. At the escalation meetings, PK analyses from active treatment participants and blinded (pooled) safety summaries will be reviewed.
All participants in Part 1 will remain at the trial site from Day -1 until their end of-trial visit (approximately 8 days for Cohorts 1-5 and 16 days for Cohort 6).
At the end of Part 1, pharmacokinetic and unblinded safety data along with dose rationale for Part 2 will be sent to the Food and Drug Administration (FDA) for review and approval. The trial will not proceed to Part 2 until the FDA provides approval.
Part 2 has a multiple ascending dose (MAD) design. The dose cohorts for Part 2 will be determined based on model predictions to determine the steady-state Cmax exposure, and safety from Part 1.
In this MAD part, each participant will be administered MK7762 or matching placebo for 28 days with corresponding PK measurements. Three dose cohorts are planned. After each dose cohort, the Sponsor and Investigator will review the PK and safety data before proceeding to the next dose level.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be included in this trial, an individual must satisfy all the following criteria:
Exclusion Criteria:
If an individual meets any of the following criteria, they are ineligible for this trial:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Part 1 of the trial (SAD/FE), up to five sequential cohorts will be enrolled to evaluate up to five escalating single doses of MK-7762; 8 participants in each cohort will be randomized (3:1) to receive MK-7762 or placebo. A sixth cohort will evaluate the effect of food on PK of single doses of MK-7762 utilizing an open-label, two-period design in 8 participants.
Drug: MK-7762 (TBD09)
Participants will receive placebos matched to MK-7762 (TBD09).
Other: Placebo
Cohort 1: 50 mg Cohort 2: 150 mg Cohort 3: 300 mg Cohort 4: 600 mg Cohort 5: TBD Cohort 6: TBD
A subset of participants from each of the 6 dosing cohorts will receive placebo.
Part 1: Percentage of Participants Reporting Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs)
An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant. A SAE is defined as any untoward medical occurrence that, at any dose: results in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent disability/incapacity or is a congenital anomaly/birth defect or is a medically significant / important event or reaction. AESIs are adverse events that the Sponsor monitored carefully and were subject to expedited reporting to the Sponsor.
Time frame: Day 1 through Day 7
Part 1: Percentage of Participants Reporting TEAEs by Severity
An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant. The intensity for each AE reported during the study were assigned to 1 of 5 categories: Grade 1 Mild symptoms, causing no or minimal interference with usual social and functional activities with intervention not indicated; Grade 2 Moderate symptoms, causing greater than minimal interference with usual social and functional activities with intervention indicated; Grade 3 Severe symptoms, causing inability to perform usual social and functional activities with intervention or hospitalization indicated; Grade 4 Potentially life-threatening symptoms, causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability, or death and Grade 5: Fatal.
Time frame: Day 1 through Day 7
Part 1: Percentage of Participants Reporting Study Drug Related TEAEs
An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant.
Time frame: Day 1 through Day 7
Part 2: FE Cohort 7: Percentage of Participants Reporting TEAEs, SAEs, and AESIs
An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant. A SAE is defined as any untoward medical occurrence that, at any dose: results in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent disability/incapacity or is a congenital anomaly/birth defect or is a medically significant / important event or reaction. AESIs are adverse events that the Sponsor monitored carefully and were subject to expedited reporting to the Sponsor.
Time frame: Up to Day 7
Part 2: FE Cohort 7: Percentage of Participants Reporting Study Drug Related TEAEs
An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant.
Time frame: Up to Day 7
Part 2: FE Cohort 7: Percentage of Participants Reporting TEAEs by Severity
An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant. The intensity for each AE reported during the study were assigned to 1 of 5 categories: Grade 1 Mild symptoms, causing no or minimal interference with usual social and functional activities with intervention not indicated; Grade 2 Moderate symptoms, causing greater than minimal interference with usual social and functional activities with intervention indicated; Grade 3 Severe symptoms, causing inability to perform usual social and functional activities with intervention or hospitalization indicated; Grade 4 Potentially life-threatening symptoms, causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability, or death and Grade 5: Fatal.
Time frame: Up to Day 7
Part 2: MAD Cohorts: Percentage of Participants Reporting TEAEs, SAEs, and AESIs
An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant. A SAE is defined as any untoward medical occurrence that, at any dose: results in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent disability/incapacity or is a congenital anomaly/birth defect or is a medically significant / important event or reaction. AESIs are adverse events that the Sponsor monitored carefully and were subject to expedited reporting to the Sponsor.
Time frame: Day 1 through Day 36.
Part 2: MAD Cohorts: Percentage of Participants Reporting TEAEs by Severity
An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant. The intensity for each AE reported during the study were assigned to 1 of 5 categories: Grade 1 Mild symptoms, causing no or minimal interference with usual social and functional activities with intervention not indicated; Grade 2 Moderate symptoms, causing greater than minimal interference with usual social and functional activities with intervention indicated; Grade 3 Severe symptoms, causing inability to perform usual social and functional activities with intervention or hospitalization indicated; Grade 4 Potentially life-threatening symptoms, causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability, or death and Grade 5: Fatal.
Time frame: Day 1 through Day 36.
Part 2: MAD Cohorts: Proportion of Participants Reporting Study Drug Related TEAEs
An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant.
Time frame: Day 1 through Day 36
Part 1: Number of Participants With Clinically Significant Changes in Hematology Parameters
Blood samples were collected for the analysis of hematology parameters: complete blood count (red blood cells, hemoglobin, platelets, and white blood cells \[WBC\]); red blood cell parameters (eg, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, and red cell distribution width); white blood cell differential (absolute counts), including neutrophils, lymphocytes, monocytes, eosinophils and basophils; and reticulocyte count
Time frame: Up to Day 7
Part 1: Number of Participants With Clinically Significant Changes in Chemistry Parameters
Blood samples were collected for the analysis of chemistry parameters: alanine transaminase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total and direct bilirubin, creatinine, blood urea nitrogen (BUN) or urea, creatine kinase, sodium, potassium, bicarbonate or CO2, chloride, glucose, and lipid profile (total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides.
Time frame: Up to Day 7
Part 1: Number of Participants With Clinically Significant Changes in Serum Coagulation Parameters
Blood samples were collected for the analysis of Serum coagulation parameters: Prothrombin Time (PT), Partial Thromboplastin Time (PTT), and international normalized ratio (INR).
Time frame: Up to Day 7
Part 1: Number of Participants With Clinically Significant Changes in Urinalysis
Urine samples were collected for the analysis of urinalysis parameters: Dipstick for potential of hydrogen (pH), specific gravity, glucose, protein, blood, leukocyte esterase, nitrites, ketones, bilirubin, and urobilinogen. Microscopic examination for red blood cells, white blood cells, casts, and bacteria was performed if urine dipstick is positive for protein, blood, leukocyte esterase, or nitrites.
Time frame: Up to Day 7
Part 1: Number of Participants With Clinically Significant Changes in Vital Parameters
Vital parameters including temperature, heart rate (HR), and blood pressure (BP) were measured in supine position. Data for number of participants with abnormal clinically significant changes for vital signs have been presented.
Time frame: Up to Day 7
Part 1: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters
ECG parameters included HR, RR interval, PR interval, QRS duration, QT interval, and QT interval corrected by Fridericia's formula (QTcF).
Time frame: Up to Day 7
Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Hematology Parameters
Blood samples were collected for the analysis of hematology parameters: complete blood count (red blood cells, hemoglobin, platelets, and WBC); red blood cell parameters (eg, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, and red cell distribution width); white blood cell differential (absolute counts), including neutrophils, lymphocytes, monocytes, eosinophils and basophils; and reticulocyte count.
Time frame: Up to Day 8
Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Hematology Parameters
Blood samples were collected for the analysis of hematology parameters: complete blood count (red blood cells, hemoglobin, platelets, and WBC); red blood cell parameters (eg, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, and red cell distribution width); white blood cell differential (absolute counts), including neutrophils, lymphocytes, monocytes, eosinophils and basophils; and reticulocyte count
Time frame: Up to Day 36
Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Chemistry Parameters
Blood samples were collected for the analysis of chemistry parameters: ALT, AST, ALP, total and direct bilirubin, creatinine, BUN or urea, creatine kinase, sodium, potassium, bicarbonate or CO2, chloride, glucose, and lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides).
Time frame: Up to Day 8
Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Chemistry Parameters
Participants were randomized to receive MK-7762 100 mg in a fed or fasted state.
Time frame: Up to Day 36
Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Serum Coagulation Parameters
Blood samples were collected for the analysis of Serum coagulation parameters: PT, PTT, and INR.
Time frame: Up to Day 8
Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Urinalysis
Urine samples were collected for the analysis of urinalysis parameters: Dipstick for pH, specific gravity, glucose, protein, blood, leukocyte esterase, nitrites, ketones, bilirubin, and urobilinogen. Microscopic examination for red blood cells, white blood cells, casts, and bacteria was performed if urine dipstick is positive for protein, blood, leukocyte esterase, or nitrites.
Time frame: Up to Day 8
Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Serum Coagulation Parameters
Blood samples were collected for the analysis of Serum coagulation parameters: PT, PTT, and INR.
Time frame: Up to Day 36
Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Urinalysis
Urine samples were collected for the analysis of urinalysis parameters: Dipstick for pH, specific gravity, glucose, protein, blood, leukocyte esterase, nitrites, ketones, bilirubin, and urobilinogen. Microscopic examination for red blood cells, white blood cells, casts, and bacteria was performed if urine dipstick is positive for protein, blood, leukocyte esterase, or nitrites
Time frame: Up to Day 36
Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Vital Parameters
Vital parameters including temperature, HR, and BP were measured in supine position. Data for number of participants with abnormal clinically significant changes for vital signs have been presented.
Time frame: Up to Day 8
Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Vital Parameters
Vital parameters including temperature, HR, and BP were measured in supine position. Data for number of participants with abnormal clinically significant changes for vital signs have been presented.
Time frame: Up to Day 36
Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in ECG Parameters
ECG parameters included HR, RR interval, PR interval, QRS duration, QT interval, and QTcF.
Time frame: Up to Day 8
Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in ECG Parameters
ECG parameters included HR, RR interval, PR interval, QRS duration, QT interval, and QTcF.
Time frame: Up to Day 36
Part 1: Maximum Plasma Drug Concentration (Cmax) of MK-7762
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.
Time frame: Day 1: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, and 12 hours post-dose and 24 and 36 hours post-dose (Day 2); Day 3: 48 hours post-dose; Day 4: 72 hours post-dose; Day 7: Within ±1-hour time window of time of study drug administration on Day 1
Part 1: Time to Maximum Plasma Drug Concentration (Tmax) of MK-7762
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.
Time frame: Day 1: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, and 12 hours post-dose and 24 and 36 hours post-dose (Day 2); Day 3: 48 hours post-dose; Day 4: 72 hours post-dose; Day 7: Within ±1-hour time window of time of study drug administration on Day 1
Part 1: Area Under the Concentration-time Curve (AUC) Calculated to Last Quantifiable Observed Sample (AUClast) of MK-7762
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.
Time frame: Day 1: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, and 12 hours post-dose and 24 and 36 hours post-dose (Day 2); Day 3: 48 hours post-dose; Day 4: 72 hours post-dose; Day 7: Within ±1-hour time window of time of study drug administration on Day 1
Part 1: AUC Over First 24h (AUC0-24) of MK-7762
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.
Time frame: Up to 24 hrs post dose
Part 1: AUC Extrapolated to Infinity (AUC0-inf) of MK-7762
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.
Time frame: Day 1: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, and 12 hours post-dose and 24 and 36 hours post-dose (Day 2); Day 3: 48 hours post-dose; Day 4: 72 hours post-dose; Day 7: Within ±1-hour time window of time of study drug administration on Day 1
Part 1: Terminal Elimination Half-life (t½) of MK-7762
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.
Time frame: Day 1: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, and 12 hours post-dose and 24 and 36 hours post-dose (Day 2); Day 3: 48 hours post-dose; Day 4: 72 hours post-dose; Day 7: Within ±1-hour time window of time of study drug administration on Day 1
Part 1: Oral Clearance (CL/F) of MK-7762
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.
Time frame: Day 1: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, and 12 hours post-dose and 24 and 36 hours post-dose (Day 2); Day 3: 48 hours post-dose; Day 4: 72 hours post-dose; Day 7: Within ±1-hour time window of time of study drug administration on Day 1
Part 1: Oral Volume of Distribution (Vd/F) of MK-7762
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.
Time frame: Day 1: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, and 12 hours post-dose and 24 and 36 hours post-dose (Day 2); Day 3: 48 hours post-dose; Day 4: 72 hours post-dose; Day 7: Within ±1-hour time window of time of study drug administration on Day 1
Part 2: FE Cohort 7: Cmax of MK-7762
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
Time frame: Day 1: pre-dose and at 1, 2, 4, 6, 8, and 12 hours post dose and 24- and 36-hours post-dose (Day 2); Day 3: 48 hours; Day 4: 72 hours; Day 5: 96 hours; Day 6: 120 hours; Day 7: 144 hours; Day 8: 168 hours post dose
Part 2: FE Cohort 7: Tmax of MK-7762
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
Time frame: Day 1: pre-dose and at 1, 2, 4, 6, 8, and 12 hours post dose and 24- and 36-hours post-dose (Day 2); Day 3: 48 hours; Day 4: 72 hours; Day 5: 96 hours; Day 6: 120 hours; Day 7: 144 hours; Day 8: 168 hours post dose
Part 2: FE Cohort 7: AUClast of MK-7762
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
Time frame: Day 1: pre-dose and at 1, 2, 4, 6, 8, and 12 hours post dose and 24- and 36-hours post-dose (Day 2); Day 3: 48 hours; Day 4: 72 hours; Day 5: 96 hours; Day 6: 120 hours; Day 7: 144 hours; Day 8: 168 hours post dose
Part 2: FE Cohort 7: AUC0-inf of MK-7762
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
Time frame: Day 1: pre-dose and at 1, 2, 4, 6, 8, and 12 hours post dose and 24- and 36-hours post-dose (Day 2); Day 3: 48 hours; Day 4: 72 hours; Day 5: 96 hours; Day 6: 120 hours; Day 7: 144 hours; Day 8: 168 hours post dose
Part 2: FE Cohort 7: AUC0-24 of MK-7762
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
Time frame: Up to 24 hours post dose
Part 2: FE Cohort 7: t½ of MK-7762
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
Time frame: Day 1: pre-dose and at 1, 2, 4, 6, 8, and 12 hours post dose and 24- and 36-hours post-dose (Day 2); Day 3: 48 hours; Day 4: 72 hours; Day 5: 96 hours; Day 6: 120 hours; Day 7: 144 hours; Day 8: 168 hours post dose
Part 2: FE Cohort 7: CL/F of MK-7762
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
Time frame: Day 1: pre-dose and at 1, 2, 4, 6, 8, and 12 hours post dose and 24- and 36-hours post-dose (Day 2); Day 3: 48 hours; Day 4: 72 hours; Day 5: 96 hours; Day 6: 120 hours; Day 7: 144 hours; Day 8: 168 hours post dose
Part 2: FE Cohort 7: Vd/F of MK-7762
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
Time frame: Day 1: pre-dose and at 1, 2, 4, 6, 8, and 12 hours post dose and 24- and 36-hours post-dose (Day 2); Day 3: 48 hours; Day 4: 72 hours; Day 5: 96 hours; Day 6: 120 hours; Day 7: 144 hours; Day 8: 168 hours post dose
Part 2: MAD Cohorts: CL/F of MK-7762
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
Time frame: Day 28: pre-dose, and at 1, 2, 4, 6, 8, and 12 hours post dose
Part 2: MAD Cohorts: Vz/F of MK-7762
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
Time frame: Day 28: pre-dose, and at 1, 2, 4, 6, 8, and 12 hours post dose
Part 2: MAD Cohorts: Accumulation Ratio (RA AUC0-24) of MK-7762
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. Accumulation ratio based on AUC 0-24 was calculated as AUC tau (Day 28) /AUC 0-24 (Day 1).
Time frame: Day 1: predose and at 1, 2, 4, 6, 8, and 12 hours post dose; Day 28: pre-dose, and at 1, 2, 4, 6, 8, and 12 hours post dose
Part 2: MAD Cohorts: Cmax of MK-7762
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
Time frame: Day 1: pre-dose and at 1, 2, 4, 6, 8, and 12 hours post dose; Day 28: pre-dose, and at 1, 2, 4, 6, 8, and 12 hours postdose
Part 2: MAD Cohorts: Tmax of MK-7762
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
Time frame: Day 1: pre-dose and at 1, 2, 4, 6, 8, and 12 hours post dose; Day 28: pre-dose, and at 1, 2, 4, 6, 8, and 12 hours postdose
Part 2: MAD Cohorts: AUC0-24 of MK-7762
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
Time frame: Up to 24 hours post dose
Part 2: MAD Cohorts: AUClast of MK-7762
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
Time frame: Day 28: pre-dose, and at 1, 2, 4, 6, 8, and 12 hours postdose
Part 2: MAD Cohorts: AUC0-inf of MK-7762
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
Time frame: Day 28: pre-dose, and at 1, 2, 4, 6, 8, and 12 hours post dose
Part 2: MAD Cohorts: AUC0-24 of MK-7762
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
Time frame: Day 28: pre-dose, and at 1, 2, 4, 6, 8, 12 and 24 hours postdose
Part 2: MAD Cohorts: t1/2 of MK-7762
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
Time frame: Day 28: pre-dose, and at 1, 2, 4, 6, 8, and 12 hours post dose
This was a first-in-human trial of MK-7762, administered orally to healthy adults. It was a randomized, placebo-controlled, two-part trial. Part 1 consisted of double-blind single ascending dose (SAD) Cohorts 1 to 5, and food effect (FE) Cohort 6 (open-label). Part 2 consisted of a FE cohort 7 (open-label) and three sequential double-blind multiple ascending dose (MAD) cohorts (Cohorts 8 to 10).
| Milestone | Part 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Placebo (Pooled) | Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fasted/Fed | Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fed/Fasted | Part 2: Cohort 7: FE 600 mg MK-7762, Sequence: Fasted/Standard/High-Fat | Part 2: Cohort 7: FE 600 mg MK-7762 Sequence: Standard/High-Fat/Fasted | Part 2: Cohort 7: FE 600 mg MK-7762 Sequence: High-Fat/Fasted/Standard | Part 2: Cohort 8: MAD MK-7762 100 mg Fasted | Part 2: Cohort 9: MAD MK-7762 300 mg Fasted | Part 2: Cohort 10: MAD MK-7762 500 mg Fasted | Part 2: Cohort 8: MAD MK-7762 100 mg Fed | Part 2: Cohort 9: MAD MK-7762 300 mg Fed | Part 2: Cohort 10: MAD MK-7762 500 mg Fed | Part 2: Placebo (Pooled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 6 | 6 | 6 | 6 | 6 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Placebo (Pooled) | Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fasted/Fed | Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fed/Fasted | Part 2: Cohort 7: FE 600 mg MK-7762, Sequence: Fasted/Standard/High-Fat | Part 2: Cohort 7: FE 600 mg MK-7762 Sequence: Standard/High-Fat/Fasted | Part 2: Cohort 7: FE 600 mg MK-7762 Sequence: High-Fat/Fasted/Standard | Part 2: Cohort 8: MAD MK-7762 100 mg Fasted | Part 2: Cohort 9: MAD MK-7762 300 mg Fasted | Part 2: Cohort 10: MAD MK-7762 500 mg Fasted | Part 2: Cohort 8: MAD MK-7762 100 mg Fed | Part 2: Cohort 9: MAD MK-7762 300 mg Fed | Part 2: Cohort 10: MAD MK-7762 500 mg Fed | Part 2: Placebo (Pooled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Placebo (Pooled) | Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fasted/Fed | Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fed/Fasted | Part 2: Cohort 7: FE 600 mg MK-7762, Sequence: Fasted/Standard/High-Fat | Part 2: Cohort 7: FE 600 mg MK-7762 Sequence: Standard/High-Fat/Fasted | Part 2: Cohort 7: FE 600 mg MK-7762 Sequence: High-Fat/Fasted/Standard | Part 2: Cohort 8: MAD MK-7762 100 mg Fasted | Part 2: Cohort 9: MAD MK-7762 300 mg Fasted | Part 2: Cohort 10: MAD MK-7762 500 mg Fasted | Part 2: Cohort 8: MAD MK-7762 100 mg Fed | Part 2: Cohort 9: MAD MK-7762 300 mg Fed | Part 2: Cohort 10: MAD MK-7762 500 mg Fed | Part 2: Placebo (Pooled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Placebo (Pooled) | Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fasted/Fed | Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fed/Fasted | Part 2: Cohort 7: FE 600 mg MK-7762, Sequence: Fasted/Standard/High-Fat | Part 2: Cohort 7: FE 600 mg MK-7762 Sequence: Standard/High-Fat/Fasted | Part 2: Cohort 7: FE 600 mg MK-7762 Sequence: High-Fat/Fasted/Standard | Part 2: Cohort 8: MAD MK-7762 100 mg Fasted | Part 2: Cohort 9: MAD MK-7762 300 mg Fasted | Part 2: Cohort 10: MAD MK-7762 500 mg Fasted | Part 2: Cohort 8: MAD MK-7762 100 mg Fed | Part 2: Cohort 9: MAD MK-7762 300 mg Fed | Part 2: Cohort 10: MAD MK-7762 500 mg Fed | Part 2: Placebo (Pooled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Placebo (Pooled) | Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fasted/Fed | Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fed/Fasted | Part 2: Cohort 7: FE 600 mg MK-7762, Sequence: Fasted/Standard/High-Fat | Part 2: Cohort 7: FE 600 mg MK-7762 Sequence: Standard/High-Fat/Fasted | Part 2: Cohort 7: FE 600 mg MK-7762 Sequence: High-Fat/Fasted/Standard | Part 2: Cohort 8: MAD MK-7762 100 mg Fasted | Part 2: Cohort 9: MAD MK-7762 300 mg Fasted | Part 2: Cohort 10: MAD MK-7762 500 mg Fasted | Part 2: Cohort 8: MAD MK-7762 100 mg Fed | Part 2: Cohort 9: MAD MK-7762 300 mg Fed | Part 2: Cohort 10: MAD MK-7762 500 mg Fed | Part 2: Placebo (Pooled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Placebo (Pooled) | Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fasted/Fed | Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fed/Fasted | Part 2: Cohort 7: FE 600 mg MK-7762, Sequence: Fasted/Standard/High-Fat | Part 2: Cohort 7: FE 600 mg MK-7762 Sequence: Standard/High-Fat/Fasted | Part 2: Cohort 7: FE 600 mg MK-7762 Sequence: High-Fat/Fasted/Standard | Part 2: Cohort 8: MAD MK-7762 100 mg Fasted | Part 2: Cohort 9: MAD MK-7762 300 mg Fasted | Part 2: Cohort 10: MAD MK-7762 500 mg Fasted | Part 2: Cohort 8: MAD MK-7762 100 mg Fed | Part 2: Cohort 9: MAD MK-7762 300 mg Fed | Part 2: Cohort 10: MAD MK-7762 500 mg Fed | Part 2: Placebo (Pooled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Placebo (Pooled) | Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fasted/Fed | Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fed/Fasted | Part 2: Cohort 7: FE 600 mg MK-7762, Sequence: Fasted/Standard/High-Fat | Part 2: Cohort 7: FE 600 mg MK-7762 Sequence: Standard/High-Fat/Fasted | Part 2: Cohort 7: FE 600 mg MK-7762 Sequence: High-Fat/Fasted/Standard | Part 2: Cohort 8: MAD MK-7762 100 mg Fasted | Part 2: Cohort 9: MAD MK-7762 300 mg Fasted | Part 2: Cohort 10: MAD MK-7762 500 mg Fasted | Part 2: Cohort 8: MAD MK-7762 100 mg Fed | Part 2: Cohort 9: MAD MK-7762 300 mg Fed | Part 2: Cohort 10: MAD MK-7762 500 mg Fed | Part 2: Placebo (Pooled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Placebo (Pooled) | Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fasted/Fed | Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fed/Fasted | Part 2: Cohort 7: FE 600 mg MK-7762, Sequence: Fasted/Standard/High-Fat | Part 2: Cohort 7: FE 600 mg MK-7762 Sequence: Standard/High-Fat/Fasted | Part 2: Cohort 7: FE 600 mg MK-7762 Sequence: High-Fat/Fasted/Standard | Part 2: Cohort 8: MAD MK-7762 100 mg Fasted | Part 2: Cohort 9: MAD MK-7762 300 mg Fasted | Part 2: Cohort 10: MAD MK-7762 500 mg Fasted | Part 2: Cohort 8: MAD MK-7762 100 mg Fed | Part 2: Cohort 9: MAD MK-7762 300 mg Fed | Part 2: Cohort 10: MAD MK-7762 500 mg Fed | Part 2: Placebo (Pooled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Placebo (Pooled) | Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fasted/Fed | Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fed/Fasted | Part 2: Cohort 7: FE 600 mg MK-7762, Sequence: Fasted/Standard/High-Fat | Part 2: Cohort 7: FE 600 mg MK-7762 Sequence: Standard/High-Fat/Fasted | Part 2: Cohort 7: FE 600 mg MK-7762 Sequence: High-Fat/Fasted/Standard | Part 2: Cohort 8: MAD MK-7762 100 mg Fasted | Part 2: Cohort 9: MAD MK-7762 300 mg Fasted | Part 2: Cohort 10: MAD MK-7762 500 mg Fasted | Part 2: Cohort 8: MAD MK-7762 100 mg Fed | Part 2: Cohort 9: MAD MK-7762 300 mg Fed | Part 2: Cohort 10: MAD MK-7762 500 mg Fed | Part 2: Placebo (Pooled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Placebo (Pooled) | Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fasted/Fed | Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fed/Fasted | Part 2: Cohort 7: FE 600 mg MK-7762, Sequence: Fasted/Standard/High-Fat | Part 2: Cohort 7: FE 600 mg MK-7762 Sequence: Standard/High-Fat/Fasted | Part 2: Cohort 7: FE 600 mg MK-7762 Sequence: High-Fat/Fasted/Standard | Part 2: Cohort 8: MAD MK-7762 100 mg Fasted | Part 2: Cohort 9: MAD MK-7762 300 mg Fasted | Part 2: Cohort 10: MAD MK-7762 500 mg Fasted | Part 2: Cohort 8: MAD MK-7762 100 mg Fed | Part 2: Cohort 9: MAD MK-7762 300 mg Fed | Part 2: Cohort 10: MAD MK-7762 500 mg Fed | Part 2: Placebo (Pooled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 8 | 8 | 8 | 8 | 8 | 12 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 8 | 8 | 8 | 8 | 8 | 12 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant. A SAE is defined as any untoward medical occurrence that, at any dose: results in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent disability/incapacity or is a congenital anomaly/birth defect or is a medically significant / important event or reaction. AESIs are adverse events that the Sponsor monitored carefully and were subject to expedited reporting to the Sponsor.
| Percentage of participants | Part 1: Cohort 1: SAD MK-7762 50 mg Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Placebo (Pooled) | Part 1: Cohort 6: FE MK-7762 300 mg Fasted | Part 1: Cohort 6: FE MK-7762 300 mg Fed |
|---|---|---|---|---|---|---|---|---|
| Any TEAE | 0 | 0 | 17 | 17 | 17 | 20 | 0 | 13 |
| Any SAE | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Any AESI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant. The intensity for each AE reported during the study were assigned to 1 of 5 categories: Grade 1 Mild symptoms, causing no or minimal interference with usual social and functional activities with intervention not indicated; Grade 2 Moderate symptoms, causing greater than minimal interference with usual social and functional activities with intervention indicated; Grade 3 Severe symptoms, causing inability to perform usual social and functional activities with intervention or hospitalization indicated; Grade 4 Potentially life-threatening symptoms, causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability, or death and Grade 5: Fatal.
| Percentage of participants | Part 1: Cohort 1: SAD MK-7762 50 mg Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Placebo (Pooled) | Part 1: Cohort 6: FE MK-7762 300 mg Fasted | Part 1: Cohort 6: FE MK-7762 300 mg Fed |
|---|---|---|---|---|---|---|---|---|
| Mild | 0 | 0 | 17 | 17 | 0 | 10 | 0 | 13 |
| Moderate | 0 | 0 | 0 | 0 | 17 | 10 | 0 | 0 |
| Severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant.
| Percentage of participants | Part 1: Cohort 1: SAD MK-7762 50 mg Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Placebo (Pooled) | Part 1: Cohort 6: FE MK-7762 300 mg Fasted | Part 1: Cohort 6: FE MK-7762 300 mg Fed |
|---|---|---|---|---|---|---|---|---|
| Part 1: Percentage of Participants Reporting Study Drug Related TEAEs | 0 | 0 | 0 | 0 | 17 | 0 | 0 | 13 |
An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant. A SAE is defined as any untoward medical occurrence that, at any dose: results in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent disability/incapacity or is a congenital anomaly/birth defect or is a medically significant / important event or reaction. AESIs are adverse events that the Sponsor monitored carefully and were subject to expedited reporting to the Sponsor.
| Percentage of participants | Part 2: Cohort 7: FE 600 mg Fasted | Part 2: Cohort 7: FE 600 mg Fed-Standard Meal | Part 2: Cohort 7: FE 600 mg Fed-High-Fat Meal |
|---|---|---|---|
| Any TEAE | 50 | 40 | 56 |
| Any SAE | 0 | 0 | 0 |
| Any AESI | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant.
| Percentage of participants | Part 2: Cohort 7: FE 600 mg Fasted | Part 2: Cohort 7: FE 600 mg Fed-Standard Meal | Part 2: Cohort 7: FE 600 mg Fed-High-fat Meal |
|---|---|---|---|
| Part 2: FE Cohort 7: Percentage of Participants Reporting Study Drug Related TEAEs | 10 | 20 | 11 |
An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant. The intensity for each AE reported during the study were assigned to 1 of 5 categories: Grade 1 Mild symptoms, causing no or minimal interference with usual social and functional activities with intervention not indicated; Grade 2 Moderate symptoms, causing greater than minimal interference with usual social and functional activities with intervention indicated; Grade 3 Severe symptoms, causing inability to perform usual social and functional activities with intervention or hospitalization indicated; Grade 4 Potentially life-threatening symptoms, causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability, or death and Grade 5: Fatal.
| Percentage of participants | Part 2: Cohort 7: FE 600 mg Fasted | Part 2: Cohort 7: FE 600 mg Fed-Standard Meal | Part 2: Cohort 7: FE 600 mg Fed-High-fat Meal |
|---|---|---|---|
| Mild | 40 | 40 | 56 |
| Moderate | 10 | 0 | 0 |
| Severe | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant. A SAE is defined as any untoward medical occurrence that, at any dose: results in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent disability/incapacity or is a congenital anomaly/birth defect or is a medically significant / important event or reaction. AESIs are adverse events that the Sponsor monitored carefully and were subject to expedited reporting to the Sponsor.
| Percentage of participants | Part 2: Cohort 8: MAD MK-7762 100 mg | Part 2: Cohort 9: MAD MK-7762 300 mg | Part 2: Cohort 10: MAD MK-7762 500 mg | Part 2: Placebo (Pooled) |
|---|---|---|---|---|
| Any TEAE | 75 | 63 | 88 | 67 |
| Any SAE | 0 | 0 | 0 | 0 |
| Any AESI | 0 | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant. The intensity for each AE reported during the study were assigned to 1 of 5 categories: Grade 1 Mild symptoms, causing no or minimal interference with usual social and functional activities with intervention not indicated; Grade 2 Moderate symptoms, causing greater than minimal interference with usual social and functional activities with intervention indicated; Grade 3 Severe symptoms, causing inability to perform usual social and functional activities with intervention or hospitalization indicated; Grade 4 Potentially life-threatening symptoms, causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability, or death and Grade 5: Fatal.
| Percentage of participants | Part 2: Cohort 8: MAD MK-7762 100 mg | Part 2: Cohort 9: MAD MK-7762 300 mg | Part 2: Cohort 10: MAD MK-7762 500 mg | Part 2: Placebo (Pooled) |
|---|---|---|---|---|
| Mild | 50 | 38 | 31 | 17 |
| Moderate | 25 | 25 | 56 | 50 |
| Severe | 0 | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant.
| Percentage of participants | Part 2: Cohort 8: MAD MK-7762 100 mg | Part 2: Cohort 9: MAD MK-7762 300 mg | Part 2: Cohort 10: MAD MK-7762 500 mg | Part 2: Placebo (Pooled) |
|---|---|---|---|---|
| Part 2: MAD Cohorts: Proportion of Participants Reporting Study Drug Related TEAEs | 25 | 13 | 19 | 17 |
Blood samples were collected for the analysis of hematology parameters: complete blood count (red blood cells, hemoglobin, platelets, and white blood cells \[WBC\]); red blood cell parameters (eg, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, and red cell distribution width); white blood cell differential (absolute counts), including neutrophils, lymphocytes, monocytes, eosinophils and basophils; and reticulocyte count
| Participants | Part 1: Cohort 1: SAD MK-7762 50 mg Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Placebo (Pooled) | Part 1: Cohort 6: FE MK-7762 300 mg Fasted | Part 1: Cohort 6: FE MK-7762 300 mg Fed |
|---|---|---|---|---|---|---|---|---|
| Part 1: Number of Participants With Clinically Significant Changes in Hematology Parameters | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Blood samples were collected for the analysis of chemistry parameters: alanine transaminase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total and direct bilirubin, creatinine, blood urea nitrogen (BUN) or urea, creatine kinase, sodium, potassium, bicarbonate or CO2, chloride, glucose, and lipid profile (total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides.
| Participants | Part 1: Cohort 1: SAD MK-7762 50 mg Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Placebo (Pooled) | Part 1: Cohort 6: FE MK-7762 300 mg Fasted | Part 1: Cohort 6: FE MK-7762 300 mg Fed |
|---|---|---|---|---|---|---|---|---|
| Part 1: Number of Participants With Clinically Significant Changes in Chemistry Parameters | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Blood samples were collected for the analysis of Serum coagulation parameters: Prothrombin Time (PT), Partial Thromboplastin Time (PTT), and international normalized ratio (INR).
| Participants | Part 1: Cohort 1: SAD MK-7762 50 mg Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Placebo (Pooled) | Part 1: Cohort 6: FE MK-7762 300 mg Fasted | Part 1: Cohort 6: FE MK-7762 300 mg Fed |
|---|---|---|---|---|---|---|---|---|
| Part 1: Number of Participants With Clinically Significant Changes in Serum Coagulation Parameters | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Urine samples were collected for the analysis of urinalysis parameters: Dipstick for potential of hydrogen (pH), specific gravity, glucose, protein, blood, leukocyte esterase, nitrites, ketones, bilirubin, and urobilinogen. Microscopic examination for red blood cells, white blood cells, casts, and bacteria was performed if urine dipstick is positive for protein, blood, leukocyte esterase, or nitrites.
| Participants | Part 1: Cohort 1: SAD MK-7762 50 mg Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Placebo (Pooled) | Part 1: Cohort 6: FE MK-7762 300 mg Fasted | Part 1: Cohort 6: FE MK-7762 300 mg Fed |
|---|---|---|---|---|---|---|---|---|
| Part 1: Number of Participants With Clinically Significant Changes in Urinalysis | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Vital parameters including temperature, heart rate (HR), and blood pressure (BP) were measured in supine position. Data for number of participants with abnormal clinically significant changes for vital signs have been presented.
| Participants | Part 1: Cohort 1: SAD MK-7762 50 mg Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Placebo (Pooled) | Part 1: Cohort 6: FE MK-7762 300 mg Fasted | Part 1: Cohort 6: FE MK-7762 300 mg Fed |
|---|---|---|---|---|---|---|---|---|
| Part 1: Number of Participants With Clinically Significant Changes in Vital Parameters | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ECG parameters included HR, RR interval, PR interval, QRS duration, QT interval, and QT interval corrected by Fridericia's formula (QTcF).
| Participants | Part 1: Cohort 1: SAD MK-7762 50 mg Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Placebo (Pooled) | Part 1: Cohort 6: FE MK-7762 300 mg Fasted | Part 1: Cohort 6: FE MK-7762 300 mg Fed |
|---|---|---|---|---|---|---|---|---|
| Part 1: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Blood samples were collected for the analysis of hematology parameters: complete blood count (red blood cells, hemoglobin, platelets, and WBC); red blood cell parameters (eg, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, and red cell distribution width); white blood cell differential (absolute counts), including neutrophils, lymphocytes, monocytes, eosinophils and basophils; and reticulocyte count.
| Participants | Part 2: Cohort 7: FE 600 mg Fasted | Part 2: Cohort 7: FE 600 mg Fed-Standard Meal | Part 2: Cohort 7: FE 600 mg Fed-High-Fat Meal |
|---|---|---|---|
| Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Hematology Parameters | 0 | 0 | 0 |
Blood samples were collected for the analysis of hematology parameters: complete blood count (red blood cells, hemoglobin, platelets, and WBC); red blood cell parameters (eg, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, and red cell distribution width); white blood cell differential (absolute counts), including neutrophils, lymphocytes, monocytes, eosinophils and basophils; and reticulocyte count
| Participants | Part 2: Cohort 8: MAD MK-7762 100 mg | Part 2: Cohort 9: MAD MK-7762 300 mg | Part 2: Cohort 10: MAD MK-7762 500 mg | Part 2: Placebo (Pooled) |
|---|---|---|---|---|
| Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Hematology Parameters | 0 | 0 | 0 | 0 |
Blood samples were collected for the analysis of chemistry parameters: ALT, AST, ALP, total and direct bilirubin, creatinine, BUN or urea, creatine kinase, sodium, potassium, bicarbonate or CO2, chloride, glucose, and lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides).
| Participants | Part 2: Cohort 7: FE 600 mg Fasted | Part 2: Cohort 7: FE 600 mg Fed-Standard Meal | Part 2: Cohort 7: FE 600 mg Fed-High-fat Meal |
|---|---|---|---|
| Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Chemistry Parameters | 0 | 0 | 0 |
Participants were randomized to receive MK-7762 100 mg in a fed or fasted state.
| Participants | Part 2: Cohort 8: MAD MK-7762 100 mg | Part 2: Cohort 9: MAD MK-7762 300 mg | Part 2: Cohort 10: MAD MK-7762 500 mg | Part 2: Placebo (Pooled) |
|---|---|---|---|---|
| Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Chemistry Parameters | 0 | 0 | 0 | 0 |
Blood samples were collected for the analysis of Serum coagulation parameters: PT, PTT, and INR.
| Participants | Part 2: Cohort 7: FE 600 mg Fasted | Part 2: Cohort 7: FE 600 mg Fed-Standard Meal | Part 2: Cohort 7: FE 600 mg Fed-High-fat Meal |
|---|---|---|---|
| Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Serum Coagulation Parameters | 0 | 0 | 0 |
Urine samples were collected for the analysis of urinalysis parameters: Dipstick for pH, specific gravity, glucose, protein, blood, leukocyte esterase, nitrites, ketones, bilirubin, and urobilinogen. Microscopic examination for red blood cells, white blood cells, casts, and bacteria was performed if urine dipstick is positive for protein, blood, leukocyte esterase, or nitrites.
| Participants | Part 2: Cohort 7: FE 600 mg Fasted | Part 2: Cohort 7: FE 600 mg Fed-Standard Meal | Part 2: Cohort 7: FE 600 mg Fed-High-fat Meal |
|---|---|---|---|
| Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Urinalysis | 0 | 0 | 0 |
Blood samples were collected for the analysis of Serum coagulation parameters: PT, PTT, and INR.
| Participants | Part 2: Cohort 8: MAD MK-7762 100 mg | Part 2: Cohort 9: MAD MK-7762 300 mg | Part 2: Cohort 10: MAD MK-7762 500 mg | Part 2: Placebo (Pooled) |
|---|---|---|---|---|
| Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Serum Coagulation Parameters | 0 | 0 | 0 | 0 |
Urine samples were collected for the analysis of urinalysis parameters: Dipstick for pH, specific gravity, glucose, protein, blood, leukocyte esterase, nitrites, ketones, bilirubin, and urobilinogen. Microscopic examination for red blood cells, white blood cells, casts, and bacteria was performed if urine dipstick is positive for protein, blood, leukocyte esterase, or nitrites
| Participants | Part 2: Cohort 8: MAD MK-7762 100 mg | Part 2: Cohort 9: MAD MK-7762 300 mg | Part 2: Cohort 10: MAD MK-7762 500 mg | Part 2: Placebo (Pooled) |
|---|---|---|---|---|
| Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Urinalysis | 0 | 0 | 0 | 0 |
Vital parameters including temperature, HR, and BP were measured in supine position. Data for number of participants with abnormal clinically significant changes for vital signs have been presented.
| Participants | Part 2: Cohort 7: FE 600 mg Fasted | Part 2: Cohort 7: FE 600 mg Fed-Standard Meal | Part 2: Cohort 7: FE 600 mg Fed-High-fat Meal |
|---|---|---|---|
| Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Vital Parameters | 0 | 0 | 0 |
Vital parameters including temperature, HR, and BP were measured in supine position. Data for number of participants with abnormal clinically significant changes for vital signs have been presented.
| Participants | Part 2: Cohort 8: MAD MK-7762 100 mg | Part 2: Cohort 9: MAD MK-7762 300 mg | Part 2: Cohort 10: MAD MK-7762 500 mg | Part 2: Placebo (Pooled) |
|---|---|---|---|---|
| Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Vital Parameters | 0 | 0 | 0 | 0 |
ECG parameters included HR, RR interval, PR interval, QRS duration, QT interval, and QTcF.
| Participants | Part 2: Cohort 7: FE 600 mg Fasted | Part 2: Cohort 7: FE 600 mg Fed-Standard Meal | Part 2: Cohort 7: FE 600 mg Fed-High-fat Meal |
|---|---|---|---|
| Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in ECG Parameters | 0 | 0 | 0 |
ECG parameters included HR, RR interval, PR interval, QRS duration, QT interval, and QTcF.
| Participants | Part 2: Cohort 8: MAD MK-7762 100 mg | Part 2: Cohort 9: MAD MK-7762 300 mg | Part 2: Cohort 10: MAD MK-7762 500 mg | Part 2: Placebo (Pooled) |
|---|---|---|---|---|
| Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in ECG Parameters | 0 | 0 | 0 | 0 |
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.
| Micromoles | Part 1: Cohort 1: SAD MK-7762 50 mg Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Cohort 6: FE MK-7762 300 mg Fasted | Part 1: Cohort 6: FE MK-7762 300 mg Fed |
|---|---|---|---|---|---|---|---|
| Part 1: Maximum Plasma Drug Concentration (Cmax) of MK-7762 | 1.440 ± 15.5 | 3.590 ± 22.1 | 7.310 ± 30.0 | 7.240 ± 27.2 | 7.770 ± 19.1 | 6.190 ± 20.0 | 9.680 ± 17.0 |
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.
| Hours | Part 1: Cohort 1: SAD MK-7762 50 mg Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Cohort 6: FE MK-7762 300 mg Fasted | Part 1: Cohort 6: FE MK-7762 300 mg Fed |
|---|---|---|---|---|---|---|---|
| Part 1: Time to Maximum Plasma Drug Concentration (Tmax) of MK-7762 | 4.50 (3.00 to 8.00) | 10.00 (5.00 to 24.00) | 10.02 (6.00 to 24.00) | 24.00 (8.00 to 36.00) | 30.01 (8.01 to 72.1) | 18.00 (6.00 to 24.00) | 7.00 (5.00 to 24.00) |
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.
| hours*micromoles | Part 1: Cohort 1: SAD MK-7762 50 mg Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Cohort 6: FE MK-7762 300 mg Fasted | Part 1: Cohort 6: FE MK-7762 300 mg Fed |
|---|---|---|---|---|---|---|---|
| Part 1: Area Under the Concentration-time Curve (AUC) Calculated to Last Quantifiable Observed Sample (AUClast) of MK-7762 | 43.90 ± 30.8 | 184.0 ± 21.2 | 309.0 ± 34.0 | 473.0 ± 30.5 | 676.0 ± 41.0 | 341.0 ± 33.5 | 394.0 ± 26.8 |
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.
| hours*micromoles | Part 1: Cohort 1: SAD MK-7762 50 mg Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Cohort 6: FE MK-7762 300 mg Fasted | Part 1: Cohort 6: FE MK-7762 300 mg Fed |
|---|---|---|---|---|---|---|---|
| Part 1: AUC Over First 24h (AUC0-24) of MK-7762 | 25.80 ± 19.6 | 71.40 ± 21.5 | 136.0 ± 25.4 | 143.0 ± 29.6 | 128.0 ± 18.1 | 119.0 ± 19.9 | 164.0 ± 17.3 |
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.
| hours*micromoles | Part 1: Cohort 1: SAD MK-7762 50 mg Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Cohort 6: FE MK-7762 300 mg Fasted | Part 1: Cohort 6: FE MK-7762 300 mg Fed |
|---|---|---|---|---|---|---|---|
| Part 1: AUC Extrapolated to Infinity (AUC0-inf) of MK-7762 | 50.50 ± 29.8 | 215.0 ± 11.8 | 326.0 ± 32.3 | 490.0 ± 30.0 | 486.0 ± 11.3 | 362.0 ± 30.2 | 406.0 ± 27.0 |
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.
| Hours | Part 1: Cohort 1: SAD MK-7762 50 mg Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Cohort 6: FE MK-7762 300 mg Fasted | Part 1: Cohort 6: FE MK-7762 300 mg Fed |
|---|---|---|---|---|---|---|---|
| Part 1: Terminal Elimination Half-life (t½) of MK-7762 | 20.3 ± 15.6 | 27.4 ± 9.4 | 21.2 ± 19.7 | 21.7 ± 13.9 | 22.2 ± 14.3 | 25.3 ± 20.0 | 24.8 ± 22.9 |
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.
| Liters per hour | Part 1: Cohort 1: SAD MK-7762 50 mg Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Cohort 6: FE MK-7762 300 mg Fasted | Part 1: Cohort 6: FE MK-7762 300 mg Fed |
|---|---|---|---|---|---|---|---|
| Part 1: Oral Clearance (CL/F) of MK-7762 | 2.36 ± 29.8 | 1.67 ± 11.8 | 2.19 ± 32.3 | 2.92 ± 30.0 | 5.89 ± 11.3 | 1.98 ± 30.2 | 1.76 ± 27.0 |
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.
| Liters | Part 1: Cohort 1: SAD MK-7762 50 mg Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Cohort 6: FE MK-7762 300 mg Fasted | Part 1: Cohort 6: FE MK-7762 300 mg Fed |
|---|---|---|---|---|---|---|---|
| Part 1: Oral Volume of Distribution (Vd/F) of MK-7762 | 69.3 ± 15.2 | 65.9 ± 14.2 | 67.1 ± 26.8 | 91.2 ± 27.4 | 188 ± 10.1 | 72.0 ± 15.8 | 62.9 ± 15.9 |
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
| Nanograms per milliliter | Part 2: Cohort 7: FE 600 mg Fasted | Part 2: Cohort 7: FE 600 mg Fed-high-fat Meal | Part 2: Cohort 7: FE 600 mg Fed-standard Meal |
|---|---|---|---|
| Part 2: FE Cohort 7: Cmax of MK-7762 | 2720 ± 18.3 | 6790 ± 10.3 | 5080 ± 25.0 |
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
| Hours | Part 2: Cohort 7: FE 600 mg Fasted | Part 2: Cohort 7: FE 600 mg Fed-high-fat Meal | Part 2: Cohort 7: FE 600 mg Fed-standard Meal |
|---|---|---|---|
| Part 2: FE Cohort 7: Tmax of MK-7762 | 24.0 (6.00 to 48.0) | 8.00 (6.00 to 24.02) | 6.08 (6.00 to 12.10) |
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
| Hours*nanograms per milliliter | Part 2: Cohort 7: FE 600 mg Fasted | Part 2: Cohort 7: FE 600 mg Fed-high-fat Meal | Part 2: Cohort 7: FE 600 mg Fed-standard Meal |
|---|---|---|---|
| Part 2: FE Cohort 7: AUClast of MK-7762 | 179000 ± 25.3 | 341000 ± 19.9 | 270000 ± 24.5 |
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
| Hours*nanograms per milliliter | Part 2: Cohort 7: FE 600 mg Fasted | Part 2: Cohort 7: FE 600 mg Fed-high-fat Meal | Part 2: Cohort 7: FE 600 mg Fed-standard Meal |
|---|---|---|---|
| Part 2: FE Cohort 7: AUC0-inf of MK-7762 | NA ± NA | NA ± NA | NA ± NA |
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
| Hours*nanograms per milliliter | Part 2: Cohort 7: FE 600 mg Fasted | Part 2: Cohort 7: FE 600 mg Fed-high-fat Meal | Part 2: Cohort 7: FE 600 mg Fed-standard Meal |
|---|---|---|---|
| Part 2: FE Cohort 7: AUC0-24 of MK-7762 | 52800 ± 20.8 | 125000 ± 9.2 | 94900 ± 22.3 |
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
| Hours | Part 2: Cohort 7: FE 600 mg Fasted | Part 2: Cohort 7: FE 600 mg Fed-High-fat Meal | Part 2: Cohort 7: FE 600 mg Fed-Standard Meal |
|---|---|---|---|
| Part 2: FE Cohort 7: t½ of MK-7762 | NA ± NA | NA ± NA | NA ± NA |
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
| Liters per hour | Part 2: Cohort 7: FE 600 mg Fasted | Part 2: Cohort 7: FE 600 mg Fed-High-fat Meal | Part 2: Cohort 7: FE 600 mg Fed-Standard Meal |
|---|---|---|---|
| Part 2: FE Cohort 7: CL/F of MK-7762 | NA ± NA | NA ± NA | NA ± NA |
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
| Liters | Part 2: Cohort 7: FE 600 mg Fasted | Part 2: Cohort 7: FE 600 mg Fed-High-fat Meal | Part 2: Cohort 7: FE 600 mg Fed-Standard Meal |
|---|---|---|---|
| Part 2: FE Cohort 7: Vd/F of MK-7762 | NA ± NA | NA ± NA | NA ± NA |
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
| Liters per hour | Part 2: Cohort 8: MAD MK-7762 100 mg Fasted | Part 2: Cohort 8: MAD MK-7762 100 mg Fed | Part 2: Cohort 9: MAD MK-7762 300 mg Fasted | Part 2: Cohort 9: MAD MK-7762 300 mg Fed | Part 2: Cohort 10: MAD MK-7762 500 mg Fasted | Part 2: Cohort 10: MAD MK-7762 500 mg Fed |
|---|---|---|---|---|---|---|
| Part 2: MAD Cohorts: CL/F of MK-7762 | 1.90 ± 20.1 | 1.70 ± 20.1 | 2.38 ± 17.7 | 1.77 ± 19.7 | 2.64 ± 16.9 | 1.79 ± 13.5 |
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
| Liters | Part 2: Cohort 8: MAD MK-7762 100 mg Fasted | Cohort 8: MAD MK-7762 100 mg Fed | Part 2: Cohort 9: MAD MK-7762 300 mg Fasted | Part 2: Cohort 9: MAD MK-7762 300 mg Fed | Part 2: Cohort 10: MAD MK-7762 500 mg Fasted | Part 2: Cohort 10: MAD MK-7762 500 mg Fed |
|---|---|---|---|---|---|---|
| Part 2: MAD Cohorts: Vz/F of MK-7762 | 62.4 ± 31.1 | 64.4 ± 13.8 | 83.7 ± 12.4 | 61.4 ± 19.5 | 90.5 ± 30.8 | 62.4 ± 14.1 |
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. Accumulation ratio based on AUC 0-24 was calculated as AUC tau (Day 28) /AUC 0-24 (Day 1).
| Ratio | Part 2: Cohort 8: MAD MK-7762 100 mg Fasted | Part 2: Cohort 8: MAD MK-7762 100 mg Fed | Part 2: Cohort 9: MAD MK-7762 300 mg Fasted | Part 2: Cohort 9: MAD MK-7762 300 mg Fed | Part 2: Cohort 10: MAD MK-7762 500 mg Fasted | Part 2: Cohort 10: MAD MK-7762 500 mg Fed |
|---|---|---|---|---|---|---|
| Part 2: MAD Cohorts: Accumulation Ratio (RA AUC0-24) of MK-7762 | 2.63 ± 21.8 | 2.73 ± 16.3 | 3.73 ± 15.6 | 2.78 ± 25.0 | 3.19 ± 37.1 | 2.54 ± 24.6 |
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
| Nanograms per milliliter | Part 2: Cohort 8: MAD MK-7762 100 mg Fasted | Part 2: Cohort 8: MAD MK-7762 100 mg Fed | Part 2: Cohort 9: MAD MK-7762 300 mg Fasted | Part 2: Cohort 9: MAD MK-7762 300 mg Fed | Part 2: Cohort 10: MAD MK-7762 500 mg Fasted | Part 2: Cohort 10: MAD MK-7762 500 mg Fed |
|---|---|---|---|---|---|---|
| Part 2: MAD Cohorts: Cmax of MK-7762 | 1040 ± 22.5 | 1180 ± 14.8 | 1880 ± 21.3 | 3550 ± 25.2 | 3100 ± 31.8 | 5860 ± 32.2 |
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
| Hours | Part 2: Cohort 8: MAD MK-7762 100 mg Fasted | Part 2: Cohort 8: MAD MK-7762 100 mg Fed | Part 2: Cohort 9: MAD MK-7762 300 mg Fasted | Part 2: Cohort 9: MAD MK-7762 300 mg Fed | Part 2: Cohort 10: MAD MK-7762 500 mg Fasted | Part 2: Cohort 10: MAD MK-7762 500 mg Fed |
|---|---|---|---|---|---|---|
| Part 2: MAD Cohorts: Tmax of MK-7762 | 6.00 (2.00 to 23.2) | 6.02 (4.00 to 12.0) | 17.6 (8.00 to 23.3) | 7.00 (6.00 to 8.03) | 17.6 (7.98 to 23.3) | 8.00 (3.98 to 12.0) |
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
| Hours*nanograms per milliliter | Part 2: Cohort 8: MAD MK-7762 100 mg Fasted | Part 2: Cohort 8: MAD MK-7762 100 mg Fed | Part 2: Cohort 9: MAD MK-7762 300 mg Fasted | Part 2: Cohort 9: MAD MK-7762 300 mg Fed | Part 2: Cohort 10: MAD MK-7762 500 mg Fasted | Part 2: Cohort 10: MAD MK-7762 500 mg Fed |
|---|---|---|---|---|---|---|
| Part 2: MAD Cohorts: AUC0-24 of MK-7762 | 20400 ± 22.9 | 21000 ± 14.8 | 35000 ± 19.4 | 62000 ± 21.2 | 60200 ± 33.3 | 107000 ± 28.4 |
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
| Hours*nanograms per milliliter | Part 2: Cohort 8: MAD MK-7762 100 mg Fasted | Part 2: Cohort 8: MAD MK-7762 100 mg Fed | Part 2: Cohort 9: MAD MK-7762 300 mg Fasted | Part 2: Cohort 9: MAD MK-7762 300 mg Fed | Part 2: Cohort 10: MAD MK-7762 500 mg Fasted | Part 2: Cohort 10: MAD MK-7762 500 mg Fed |
|---|---|---|---|---|---|---|
| Part 2: MAD Cohorts: AUClast of MK-7762 | 108000 ± 17.1 | 124000 ± 32.3 | 324000 ± 24.9 | 374000 ± 32.6 | 526000 ± 27.1 | 653000 ± 16.3 |
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
| Hours*nanograms per milliliter | Part 2: Cohort 8: MAD MK-7762 100 mg Fasted | Part 2: Cohort 8: MAD MK-7762 100 mg Fed | Part 2: Cohort 9: MAD MK-7762 300 mg Fasted | Part 2: Cohort 9: MAD MK-7762 300 mg Fed | Part 2: Cohort 10: MAD MK-7762 500 mg Fasted | Part 2: Cohort 10: MAD MK-7762 500 mg Fed |
|---|---|---|---|---|---|---|
| Part 2: MAD Cohorts: AUC0-inf of MK-7762 | 110000 ± 16.5 | 127000 ± 32.1 | 326000 ± 24.9 | 377000 ± 32.5 | 532000 ± 28.0 | 657000 ± 16.4 |
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
| Hours*nanograms per milliliter | Part 2: Cohort 8: MAD MK-7762 100 mg Fasted | Part 2: Cohort 8: MAD MK-7762 100 mg Fed | Part 2: Cohort 9: MAD MK-7762 300 mg Fasted | Part 2: Cohort 9: MAD MK-7762 300 mg Fed | Part 2: Cohort 10: MAD MK-7762 500 mg Fasted | Part 2: Cohort 10: MAD MK-7762 500 mg Fed |
|---|---|---|---|---|---|---|
| Part 2: MAD Cohorts: AUC0-24 of MK-7762 | 52600 ± 20.1 | 58900 ± 20.1 | 126000 ± 17.7 | 169000 ± 19.7 | 189000 ± 16.9 | 279000 ± 13.5 |
Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.
| Hours | Part 2: Cohort 8: MAD MK-7762 100 mg Fasted | Part 2: Cohort 8: MAD MK-7762 100 mg Fed | Part 2: Cohort 9: MAD MK-7762 300 mg Fasted | Part 2: Cohort 9: MAD MK-7762 300 mg Fed | Part 2: Cohort 10: MAD MK-7762 500 mg Fasted | Part 2: Cohort 10: MAD MK-7762 500 mg Fed |
|---|---|---|---|---|---|---|
| Part 2: MAD Cohorts: t1/2 of MK-7762 | 22.8 ± 15.4 | 26.3 ± 18.5 | 24.4 ± 11.5 | 24.0 ± 24.6 | 23.7 ± 31.7 | 24.2 ± 21.1 |
Collected over Part 1 Cohorts 1-5 and Placebo: up to 7 days, Part 1 Cohort 6: up to 22 days (up to 7 days for each Crossover Period and 8 days Washout), Part 2 Cohort 7: up to 40 days (up to 8 days for each Crossover Period and 8 days for each Washout), Part 2 Cohorts 8-10 and Placebo: up to 36 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) Fasted | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part 1: Placebo (Pooled) | 0/10 (0%) | 0/10 (0%) | 2/10 (20%) |
| Part 1: Cohort 6: FE MK-7762 300 mg Fasted | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Part 1: Cohort 6: FE MK-7762 300 mg Fed | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Part 2: Cohort 7: FE 600 mg Fasted | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| Part 2: Cohort 7: FE 600 mg Fed-Standard Meal | 0/10 (0%) | 0/10 (0%) | 4/10 (40%) |
| Part 2: Cohort 7: FE 600 mg Fed High-fat Meal | 0/9 (0%) | 0/9 (0%) | 5/9 (55.6%) |
| Part 2: Cohort 8: MAD MK-7762 100 mg | 0/16 (0%) | 0/16 (0%) | 12/16 (75%) |
| Part 2: Cohort 9: MAD MK-7762 300 mg | 0/16 (0%) | 0/16 (0%) | 10/16 (62.5%) |
| Part 2: Cohort 10: MAD MK-7762 500 mg | 0/16 (0%) | 0/16 (0%) | 14/16 (87.5%) |
| Part 2: Placebo (Pooled) | 0/12 (0%) | 0/12 (0%) | 8/12 (66.7%) |
| Event | Part 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Placebo (Pooled) | Part 1: Cohort 6: FE MK-7762 300 mg Fasted | Part 1: Cohort 6: FE MK-7762 300 mg Fed | Part 2: Cohort 7: FE 600 mg Fasted | Part 2: Cohort 7: FE 600 mg Fed-Standard Meal | Part 2: Cohort 7: FE 600 mg Fed High-fat Meal | Part 2: Cohort 8: MAD MK-7762 100 mg | Part 2: Cohort 9: MAD MK-7762 300 mg | Part 2: Cohort 10: MAD MK-7762 500 mg | Part 2: Placebo (Pooled) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 | 0/3 | 0/5 | 2/4 | 2/4 | 3/3 | 0/16 | 0/16 | 0/16 | 0/12 |
| Weight DecreasedInvestigations | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 | 0/3 | 0/5 | 0/4 | 0/4 | 0/3 | 8/16 | 4/16 | 7/16 | 2/12 |
| FatigueGeneral disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 | 0/3 | 0/5 | 1/4 | 1/4 | 1/3 | 1/16 | 0/16 | 0/16 | 0/12 |
| Medical Device Site ReactionGeneral disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 | 0/3 | 0/5 | 1/4 | 1/4 | 1/3 | 2/16 | 2/16 | 0/16 | 1/12 |
| ColitisGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 | 0/3 | 0/5 | 1/4 | 0/4 | 0/3 | 0/16 | 0/16 | 0/16 | 0/12 |
| NauseaGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 | 0/3 | 0/5 | 1/4 | 0/4 | 0/3 | 0/16 | 0/16 | 0/16 | 0/12 |
| COVID-19Infections and infestations | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 | 0/3 | 0/5 | 1/4 | 1/4 | 0/3 | 1/16 | 0/16 | 0/16 | 0/12 |
| Nasal CongestionRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 | 0/3 | 0/5 | 0/4 | 1/4 | 0/3 | 0/16 | 0/16 | 0/16 | 0/12 |
| Throat IrritationRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 | 0/3 | 0/5 | 0/4 | 1/4 | 0/3 | 0/16 | 0/16 | 0/16 | 0/12 |
| Abdominal DiscomfortGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 | 0/3 | 1/5 | 0/4 | 0/4 | 0/3 | 0/16 | 0/16 | 0/16 | 1/12 |
Safety Population comprised of all participants who received the study intervention.
| Age, Continuous(Years) | Part 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Placebo (Pooled) | Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fasted/Fed | Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fed/Fasted | Part 2: Cohort 7: FE 600 mg MK-7762, Sequence: Fasted/Standard/High-Fat | Part 2: Cohort 7: FE 600 mg MK-7762 Sequence: Standard/High-Fat/Fasted | Part 2: Cohort 7: FE 600 mg MK-7762 Sequence: High-Fat/Fasted/Standard | Part 2: Cohort 8: MAD MK-7762 100 mg Fasted | Part 2: Cohort 9: MAD MK-7762 300 mg Fasted | Part 2: Cohort 10: MAD MK-7762 500 mg Fasted | Part 2: Cohort 8: MAD MK-7762 100 mg Fed | Part 2: Cohort 9: MAD MK-7762 300 mg Fed | Part 2: Cohort 10: MAD MK-7762 500 mg Fed | Part 2: Placebo (Pooled) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 33.3 ± 6.9 | 35.0 ± 9.3 | 42.0 ± 11.8 | 41.5 ± 10.6 | 40.2 ± 6.4 | 30.9 ± 9.0 | 40.0 ± 9.2 | 34.4 ± 10.4 | 34.5 ± 6.1 | 43.3 ± 2.8 | 36.7 ± 7.5 | 32.3 ± 7.61 | 39.9 ± 10.2 | 38.3 ± 7.15 | 38.9 ± 7.12 | 40.9 ± 10.1 | 41.5 ± 6.80 | 41.0 ± 7.0 | 37.9 ± 8.1 |
| Sex: Female, Male(Participants) | Part 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Placebo (Pooled) | Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fasted/Fed | Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fed/Fasted | Part 2: Cohort 7: FE 600 mg MK-7762, Sequence: Fasted/Standard/High-Fat | Part 2: Cohort 7: FE 600 mg MK-7762 Sequence: Standard/High-Fat/Fasted | Part 2: Cohort 7: FE 600 mg MK-7762 Sequence: High-Fat/Fasted/Standard | Part 2: Cohort 8: MAD MK-7762 100 mg Fasted | Part 2: Cohort 9: MAD MK-7762 300 mg Fasted | Part 2: Cohort 10: MAD MK-7762 500 mg Fasted | Part 2: Cohort 8: MAD MK-7762 100 mg Fed | Part 2: Cohort 9: MAD MK-7762 300 mg Fed | Part 2: Cohort 10: MAD MK-7762 500 mg Fed | Part 2: Placebo (Pooled) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 2 | 1 | 2 | 2 | 15 |
| Male | 5 | 6 | 4 | 5 | 5 | 10 | 3 | 5 | 4 | 3 | 3 | 7 | 8 | 7 | 6 | 7 | 6 | 10 | 104 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Placebo (Pooled) | Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fasted/Fed | Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fed/Fasted | Part 2: Cohort 7: FE 600 mg MK-7762, Sequence: Fasted/Standard/High-Fat | Part 2: Cohort 7: FE 600 mg MK-7762 Sequence: Standard/High-Fat/Fasted | Part 2: Cohort 7: FE 600 mg MK-7762 Sequence: High-Fat/Fasted/Standard | Part 2: Cohort 8: MAD MK-7762 100 mg Fasted | Part 2: Cohort 9: MAD MK-7762 300 mg Fasted | Part 2: Cohort 10: MAD MK-7762 500 mg Fasted | Part 2: Cohort 8: MAD MK-7762 100 mg Fed | Part 2: Cohort 9: MAD MK-7762 300 mg Fed | Part 2: Cohort 10: MAD MK-7762 500 mg Fed | Part 2: Placebo (Pooled) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 2 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 2 | 2 | 2 | 1 | 1 | 2 | 6 | 25 |
| Not Hispanic or Latino | 5 | 6 | 4 | 5 | 5 | 9 | 3 | 4 | 3 | 3 | 3 | 6 | 6 | 6 | 7 | 7 | 6 | 6 | 94 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) Fasted | Part 1: Cohort 2: SAD MK-7762 150 mg Fasted | Part 1: Cohort 3: SAD MK-7762 300 mg Fasted | Part 1: Cohort 4: SAD MK-7762 600 mg Fasted | Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted | Part 1: Placebo (Pooled) | Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fasted/Fed | Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fed/Fasted | Part 2: Cohort 7: FE 600 mg MK-7762, Sequence: Fasted/Standard/High-Fat | Part 2: Cohort 7: FE 600 mg MK-7762 Sequence: Standard/High-Fat/Fasted | Part 2: Cohort 7: FE 600 mg MK-7762 Sequence: High-Fat/Fasted/Standard | Part 2: Cohort 8: MAD MK-7762 100 mg Fasted | Part 2: Cohort 9: MAD MK-7762 300 mg Fasted | Part 2: Cohort 10: MAD MK-7762 500 mg Fasted | Part 2: Cohort 8: MAD MK-7762 100 mg Fed | Part 2: Cohort 9: MAD MK-7762 300 mg Fed | Part 2: Cohort 10: MAD MK-7762 500 mg Fed | Part 2: Placebo (Pooled) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 3 | 2 | 1 | 2 | 4 | 5 | 0 | 1 | 2 | 1 | 1 | 3 | 3 | 2 | 4 | 2 | 2 | 3 | 41 |
| White | 2 | 4 | 5 | 4 | 2 | 5 | 3 | 3 | 1 | 3 | 2 | 4 | 4 | 5 | 4 | 6 | 5 | 8 | 70 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Feb 2023 to primary completion in Mar 2024, 13 months.
Results were first posted in Jun 2026, 2 years 2 months after primary completion.
Of 40 non-industry phase 1 interventional studies under Tuberculosis, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 30. This study's 13 months is close to that.
Counting every sponsor, half of 60 studies reached it within 10 months; a quarter within 3 and three quarters within 25.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gates Medical Research Institute